New ointment could treat larger patches of Sun-Damaged skin
NCT ID NCT06135415
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tested an ointment called tirbanibulin (Klisyri®) on adults with actinic keratosis, a common precancerous skin condition caused by sun exposure. The trial included 280 participants and applied the ointment to larger skin areas (up to 100 cm²) on the face or balding scalp. The goal was to see if it safely reduces the number of lesions compared to a placebo ointment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirbanibulin ointment (Klisyri®)
What this could lead to
If successful, this could provide a treatment option for larger areas of actinic keratosis, reducing the number of precancerous skin lesions.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The treatment may cause skin reactions and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOSIS, ACTINIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1
Bad Bentheim, Germany
-
Site 10
Warsaw, Poland
-
Site 11
Warsaw, Poland
-
Site 12
Barcelona, Spain
-
Site 13
Madrid, Spain
-
Site 14
Barcelona, Spain
-
Site 15
Valencia, Spain
-
Site 16
Zaragoza, Spain
-
Site 17
Augsburg, Germany
-
Site 18
Dresden, Germany
-
Site 19
Brescia, Italy
-
Site 2
Hamburg, Germany
-
Site 20
Roma, Italy
-
Site 21
Roma, Italy
-
Site 22
Pisa, Italy
-
Site 23
Florence, Italy
-
Site 24
Bari, Italy
-
Site 25
Bologna, Italy
-
Site 26
Cagliari, Italy
-
Site 27
Reggio Emilia, Italy
-
Site 28
Maastricht, Netherlands
-
Site 29
Heemstede, Netherlands
-
Site 3
Bochum, Germany
-
Site 30
Ossy, Poland
-
Site 31
Krakow, Poland
-
Site 32
Salamanca, Spain
-
Site 33
Granada, Spain
-
Site 34
Barcelona, Spain
-
Site 35
Valencia, Spain
-
Site 4
Mahlow, Germany
-
Site 5
Hamburg, Germany
-
Site 6
Wuppertal, Germany
-
Site 7
Roma, Italy
-
Site 8
Wroclaw, Poland
-
Site 9
Warsaw, Poland